116 related articles for article (PubMed ID: 26771938)
21. Enzalutamide Versus Bicalutamide in Castration-Resistant Prostate Cancer: The STRIVE Trial.
Penson DF; Armstrong AJ; Concepcion R; Agarwal N; Olsson C; Karsh L; Dunshee C; Wang F; Wu K; Krivoshik A; Phung D; Higano CS
J Clin Oncol; 2016 Jun; 34(18):2098-106. PubMed ID: 26811535
[TBL] [Abstract][Full Text] [Related]
22. Increased Expression of ALDH1A1 in Prostate Cancer is Correlated With Tumor Aggressiveness: A Tissue Microarray Study of Iranian Patients.
Kalantari E; Saadi FH; Asgari M; Shariftabrizi A; Roudi R; Madjd Z
Appl Immunohistochem Mol Morphol; 2017 Sep; 25(8):592-598. PubMed ID: 26894647
[TBL] [Abstract][Full Text] [Related]
23. Racial Differences in the Association Between Preoperative Serum Cholesterol and Prostate Cancer Recurrence: Results from the SEARCH Database.
Allott EH; Howard LE; Aronson WJ; Terris MK; Kane CJ; Amling CL; Cooperberg MR; Freedland SJ
Cancer Epidemiol Biomarkers Prev; 2016 Mar; 25(3):547-54. PubMed ID: 26809276
[TBL] [Abstract][Full Text] [Related]
24. Combined loss of TFF3 and PTEN is associated with lethal outcome and overall survival in men with prostate cancer.
Abou-Ouf H; Ghosh S; Box A; Palanisamy N; Bismar TA
J Cancer Res Clin Oncol; 2019 Jul; 145(7):1751-1759. PubMed ID: 31129769
[TBL] [Abstract][Full Text] [Related]
25. MUC1 is upregulated in advanced prostate cancer and is an independent prognostic factor.
Genitsch V; Zlobec I; Thalmann GN; Fleischmann A
Prostate Cancer Prostatic Dis; 2016 Sep; 19(3):242-7. PubMed ID: 27165976
[TBL] [Abstract][Full Text] [Related]
26. Large-scale evaluation of SLC18A2 in prostate cancer reveals diagnostic and prognostic biomarker potential at three molecular levels.
Haldrup C; Lynnerup AS; Storebjerg TM; Vang S; Wild P; Visakorpi T; Arsov C; Schulz WA; Lindberg J; Grönberg H; Egevad L; Borre M; Ørntoft TF; Høyer S; Sørensen KD
Mol Oncol; 2016 Jun; 10(6):825-37. PubMed ID: 26905753
[TBL] [Abstract][Full Text] [Related]
27. A TMEFF2-regulated cell cycle derived gene signature is prognostic of recurrence risk in prostate cancer.
Georgescu C; Corbin JM; Thibivilliers S; Webb ZD; Zhao YD; Koster J; Fung KM; Asch AS; Wren JD; Ruiz-Echevarría MJ
BMC Cancer; 2019 May; 19(1):423. PubMed ID: 31060542
[TBL] [Abstract][Full Text] [Related]
28. Overexpression of Periostin in Tumor Biopsy Samples Is Associated With Prostate Cancer Phenotype and Clinical Outcome.
Cattrini C; Rubagotti A; Nuzzo PV; Zinoli L; Salvi S; Boccardo S; Perachino M; Cerbone L; Vallome G; Latocca MM; Zanardi E; Boccardo F
Clin Genitourin Cancer; 2018 Dec; 16(6):e1257-e1265. PubMed ID: 30170989
[TBL] [Abstract][Full Text] [Related]
29. A Biopsy-based 17-gene Genomic Prostate Score as a Predictor of Metastases and Prostate Cancer Death in Surgically Treated Men with Clinically Localized Disease.
Van Den Eeden SK; Lu R; Zhang N; Quesenberry CP; Shan J; Han JS; Tsiatis AC; Leimpeter AD; Lawrence HJ; Febbo PG; Presti JC
Eur Urol; 2018 Jan; 73(1):129-138. PubMed ID: 28988753
[TBL] [Abstract][Full Text] [Related]
30. MicroRNA-30d promotes angiogenesis and tumor growth via MYPT1/c-JUN/VEGFA pathway and predicts aggressive outcome in prostate cancer.
Lin ZY; Chen G; Zhang YQ; He HC; Liang YX; Ye JH; Liang YK; Mo RJ; Lu JM; Zhuo YJ; Zheng Y; Jiang FN; Han ZD; Wu SL; Zhong WD; Wu CL
Mol Cancer; 2017 Feb; 16(1):48. PubMed ID: 28241827
[TBL] [Abstract][Full Text] [Related]
31. High expression of PDGFR-β in prostate cancer stroma is independently associated with clinical and biochemical prostate cancer recurrence.
Nordby Y; Richardsen E; Rakaee M; Ness N; Donnem T; Patel HR; Busund LT; Bremnes RM; Andersen S
Sci Rep; 2017 Feb; 7():43378. PubMed ID: 28233816
[TBL] [Abstract][Full Text] [Related]
32. Observed correlation between the expression levels of catalytic subunit, Cβ2, of cyclic adenosine monophosphate-dependent protein kinase and prostate cancer aggressiveness.
Moen LV; Ramberg H; Zhao S; Grytli HH; Sveen A; Berge V; Skotheim RI; Taskén KA; Skålhegg BS
Urol Oncol; 2017 Mar; 35(3):111.e1-111.e8. PubMed ID: 27838142
[TBL] [Abstract][Full Text] [Related]
33. High Caveolin-1 Expression in Tumor Stroma Is Associated with a Favourable Outcome in Prostate Cancer Patients Managed by Watchful Waiting.
Hammarsten P; Dahl Scherdin T; Hägglöf C; Andersson P; Wikström P; Stattin P; Egevad L; Granfors T; Bergh A
PLoS One; 2016; 11(10):e0164016. PubMed ID: 27764093
[TBL] [Abstract][Full Text] [Related]
34. Overexpression of Pleomorphic Adenoma Gene-Like 2 Is a Novel Poor Prognostic Marker of Prostate Cancer.
Guo J; Wang M; Wang Z; Liu X
PLoS One; 2016; 11(8):e0158667. PubMed ID: 27537362
[TBL] [Abstract][Full Text] [Related]
35. c-Myb Enhances Breast Cancer Invasion and Metastasis through the Wnt/β-Catenin/Axin2 Pathway.
Li Y; Jin K; van Pelt GW; van Dam H; Yu X; Mesker WE; Ten Dijke P; Zhou F; Zhang L
Cancer Res; 2016 Jun; 76(11):3364-75. PubMed ID: 27197202
[TBL] [Abstract][Full Text] [Related]
36. A leukemia-protective germline variant mediates chromatin module formation via transcription factor nucleation.
Llimos G; Gardeux V; Koch U; Kribelbauer JF; Hafner A; Alpern D; Pezoldt J; Litovchenko M; Russeil J; Dainese R; Moia R; Mahmoud AM; Rossi D; Gaidano G; Plass C; Lutsik P; Gerhauser C; Waszak SM; Boettiger A; Radtke F; Deplancke B
Nat Commun; 2022 Apr; 13(1):2042. PubMed ID: 35440565
[TBL] [Abstract][Full Text] [Related]
37. Novel Gene Signatures Predictive of Patient Recurrence-Free Survival and Castration Resistance in Prostate Cancer.
A J; Zhang B; Zhang Z; Hu H; Dong JT
Cancers (Basel); 2021 Feb; 13(4):. PubMed ID: 33671634
[TBL] [Abstract][Full Text] [Related]
38. Grading Evolution and Contemporary Prognostic Biomarkers of Clinically Significant Prostate Cancer.
Sopyllo K; Erickson AM; Mirtti T
Cancers (Basel); 2021 Feb; 13(4):. PubMed ID: 33562508
[TBL] [Abstract][Full Text] [Related]
39. Assessment of biochemical recurrence of prostate cancer (Review).
Lin X; Kapoor A; Gu Y; Chow MJ; Xu H; Major P; Tang D
Int J Oncol; 2019 Dec; 55(6):1194-1212. PubMed ID: 31638194
[TBL] [Abstract][Full Text] [Related]
40. MEIS1 and MEIS2 Expression and Prostate Cancer Progression: A Role For HOXB13 Binding Partners in Metastatic Disease.
Bhanvadia RR; VanOpstall C; Brechka H; Barashi NS; Gillard M; McAuley EM; Vasquez JM; Paner G; Chan WC; Andrade J; De Marzo AM; Han M; Szmulewitz RZ; Vander Griend DJ
Clin Cancer Res; 2018 Aug; 24(15):3668-3680. PubMed ID: 29716922
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
